Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into one of the world’s largest biotechnology companies and the global leader in in-vitro diagnostics.
Roche is a global pioneer in pharmaceuticals and diagnostics focused an advancing scien ce to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have mode Roche the leader in personalized healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is one of the the world's langest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirtytwo medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognized as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and employes about 100,000 people worldwide. In 2021, Roche invested CHF 13,7 billion in R&D and posted sales of CHF 62.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. Roche has been operating in Italy for over 125 years and our employees are engaged in bringing every day therapeutic solutions to patients, to prevent, diagnose and treat diseases, giving a sustainable contribution to society. The three divisions of the Group are active in Italy: Roche S.p.A., Roche Diagnostics S.p.A. and Roche Diabetes Care S.p.A. As global leader in healthcare, for Roche the scientific research is the engine of a long history of innovation, to bring cutting-edge therapeutic solutions able to improve the quality of life of patients, thus contributing to transform the future of medicine. The combination of pharmaceutical and diagnostic expertise within the same organization has led Roche to be at the forefront of personalized medicine. Research and innovation have always been our answer to healthcare challenges, as evidenced by the development of a unique portfolio in highly complex diseases, such as tumors, hemophilia, autism, Alzheimer's, spinal muscular atrophy (SMA) and multiple sclerosis. For years, Roche has been at the top of the world rankings for investments in R&D with investments, thus offering specific diagnostic paths and cutting-edge treatments to patients at no cost to families or the National Health Service.
Why Federated Innovation?
Our vision in Federated Innovation @MIND is to contribute to the increase health and wellbeing by leveraging advanced technologies (big data and AI, VBHC and HC sustainablility) along the patient/citizen journey from prevention to cure. Our main strategic domain focus thematic area are: Value based medicine, Data & Digital in Healthcare, Collaboration and co-innovation.